guys may mga narinig nba kau about LIZADA KRG? madami kasi kung nbsa sa dyaryo and nagsearch ndn aku sa net, mdaming testimonial dun n nagsabi from reactivee hapa b, nag non reactive sila, bukas pupunta ku sa office nila pra itry yung medication, hoping n mapagaling dn nila ku, kung anu mang maging resulta post ku dto, wag tau mwalan ng pag asa!
hi, pls try the natural way, Sante PureBarley. Im a chronic hepa B but healthy carrier, nagtake na ako ng Lizada KRG pero pataas ng pataas counts ko dati 3,854 lng taz naging 7,626 last july 12, 2012 tapos pakiramdam ko nanghihina ako thats why i'l stop taking it, nakasampu bote 50grms din naconsumed ko nun pero wala pa din, nitong march 25,2013 nadiscover ko ung sante purebarley tru net nagustuhan ko ang products nila kaya nagpamember ako agad pampaboost ng immune system and madami na gumaling kaya sumubok ako, 3 weeks na ako umiinom nito then kanina lng umaga nagpatest ulit ako ng dugo counts ko nasa 7,471 bumaba ng 155 imagine 3 weeks pa lng ako umiinom nito may low changes na agad sa counts ko, thanks God kasi nadiscover ko ito sante Purebarley and gusto ko ishare itong lahat sa inyo na wag tau mawawalan ng pag asa. Para sa mga gusto magtake ng purebarley pwede nyo ako itxt sa 09175432788. Thanks and GodBless us always :-)
kalokohan lang ang ginseng na yan nabiktima rin ako ni DIGNA LIZADA sayang lang ang pera at nabiktima niya rin ang ibang kakillala ko na may kaso rin ng hepa b ganon din ang reklamo walang rin nangyari..
ESTABLISHMENT OF A POTENT ANTI-HBSAG RESPONSE AND DURABLE IMMUNOLOGICAL CONTROL OF VIREMIA WITH SHORT TERM IMMUNOTHERAPY AFTER REP 9AC'- INDUCED HBSAG SEROCLEARANCE IN CHRONIC HBV INFECTION
M. Al-Mahtab1, M. Bazinet2, A. Vaillant2*
1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, QC, Canada. ****@****
Background: HBsAg is known to block cytokine responses and its persistent circulation during immunotherapy may block immune stimulation in patients with chronic HBV. REP 9AC' is a nucleic acid-based polymer (NAP) that clears serum HBsAg by blocking HBV subviral particle formation and release. The ability of add-on immunotherapy after REP 9AC'- induced HBsAg seroclearance to establish a permanent immunological control of chronic HBV infection was examined.
Methods: Add on immunotherapy to existing REP 9AC' therapy was initiated in patients experiencing HBsAg seroclearance with persistent serum HBV DNA. Immmunotherapy consisted of thymosin α1 (Zadaxin™) or pegylated interferon α-2a (Pegasys™). Virologic responses were monitored by measuring serum HBV DNA (Roche Cobas™), serum HBsAg and serum anti-HBs (Abbott Architect™).
Results: REP 9AC'- induced HBsAg seroclearance was achieved in most patients with 8-16 weeks of treatment and was accompanied by the appearance of moderate free anti-HBs titers (50-60 mIU/ml) and reductions in serum HBV DNA (to 1000-3000 CPM). Addition of Zadaxin™ or Pegasys™ to REP 9AC' therapy resulted in rapid and profound increases in anti-HBs titers after as little as 6 weeks of immunotherapy to titers comparable to or greater than those observed in healthy patients with a strong vaccine response. In 8 of 9 patients, all treatment was halted after 13 - 27 weeks of immunotherapy exposure. In these patients, anti HBs titers off-treatment are currently comparable to or exceed those observed in uninfected subjects with a strong HBV vaccine response up to 4 months off treatment. Additionally, serum HBV DNA is also supressed or is declining in all of these patients off-treatment. Currently, serum HBV DNA levels have reached < 500 cpm (2 patients), < 150 cpm (1 patient) or < 116 cpm (LLOQ) in the remaining 5 patients.
Conclusions: REP 9AC'-induced HBsAg seroclearance appears to potentiate the immunostimulatory effects of either Zadaxin™ or Pegasys ™ in all patients, suggesting that circulating HBsAg may play a direct role in blocking the stimulation of immune function by immunotherapy. Short term exposure to immunotherapy in the absence of HBsAg may induce permanent immunological control of HBV infection in most patients.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.